← Back to Search
Circulating TIMP-1 Is Associated With Hematoma Volume In Patients With Spontaneous Intracranial Hemorrhage
M. Navarro-Oviedo, R. Muñoz-Arrondo, B. Zandio, J. Marta-Enguita, Anna Bonaterra-Pastra, J. Rodríguez, C. Roncal, J. Paramo, E. Toledo, J. Montaner, M. Hernández-Guillamon, J. Orbe
Published 2020 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Matrix metalloproteinases (MMPs) are proteolytic zinc-endopeptidases regulated by tissue Inhibitors of matrix metalloproteinases (TIMPs). We evaluated the potential of MMPs and TIMPs as clinical tools for Intracranial Haemorrhage (ICH). Spontaneous non‐traumatic ICH patients were recruited from two hospitals: Complejo Hospitalario de Navarra (CHN = 29) and Vall d´Hebron (VdH = 76). Plasmatic levels of MMP-1, −2, −7, −9, −10 and TIMP-1 and their relationship with clinical, radiological and functional variables were evaluated. We further studied the effect of TIMP-1 (0.05–0.2 mg/Kg) in an experimental tail-bleeding model. In CHN, TIMP-1 was associated with admission-hematoma volume and MMP-7 was elevated in patients with deep when compared to lobar hematoma. In VdH, admission-hematoma volume was associated with TIMP-1 and MMP-7. When data from both hospitals were combined, we observed that an increase in 1 ng/ml in TIMP-1 was associated with an increase of 0.14 ml in haemorrhage (combined β = 0.14, 95% CI = 0.08–0.21). Likewise, mice receiving TIMP-1 (0.2 mg/Kg) showed a shorter bleeding time (p < 0.01). Therefore, the association of TIMP-1 with hematoma volume in two independent ICH cohorts suggests its potential as ICH biomarker. Moreover, increased TIMP-1 might not be sufficient to counterbalance MMPs upregulation indicating that TIMP-1 administration might be a beneficial strategy for ICH.
This paper references
K. Johnson (1984)
Matrix metalloproteinase-9 in cerebral aneurysms.
S. Kim (1997)
Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery
A 12-year follow-up study of treated obese children in Japan
K. Togashi (2002)
Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury
Qinglang Li (2002)
Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage.
S. Abilleira (2003)
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
E. Waubant (2003)
John Wang Montclair (2004)
Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage: Relationship to Clinical and Radiological Outcome
J. Álvarez-Sabín (2004)
Handbook of Proteolytic Enzymes: Second Edition. Handbook of Proteolytic Enzymes: Second Edition
A J Barrett (2004)
Multiple roles for MMPs and TIMPs in cerebral ischemia
L. A. Cunningham (2005)
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
J. George (2005)
Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage.
H. Huttner (2006)
In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation
J. Sellner (2006)
Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and -2 in ischemic brain injury
S. Magnoni (2007)
Tissue Inhibitor of Metalloproteinases Protect Blood—Brain Barrier Disruption in Focal Cerebral Ischemia
M. Fujimoto (2008)
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.
K. Brew (2010)
An ancient family with structural and functional diversity
K. Brew (2010)
Update in Intracerebral Hemorrhage
M. Aguilar (2011)
Update in Intracerebral Hemorrhage. The Neurohospitalist
M I Aguilar (2011)
The EURODIAB Prospective Complications Study
G. Gruden (2012)
MMP‐2/MMP‐9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathy‐Associated Hemorrhagic Stroke
M. Hernández-Guillamon (2012)
Matrix Metalloproteinases in Human Spontaneous Intracerebral Hemorrhage: An Update
M. Florczak-Rzepka (2012)
Differential Regulation of Matrix-Metalloproteinases and Their Tissue Inhibitors in Patients with Aneurysmal Subarachnoid Hemorrhage
M. Fischer (2013)
Association of Molecular Markers With Perihematomal Edema and Clinical Outcome in Intracerebral Hemorrhage
N. Li (2013)
Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients
M. Toni (2013)
Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury
L. Lorente (2014)
National Institutes of Health Stroke Scale (NIHSS).
L. Kwah (2014)
Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
A. Biffi (2015)
Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction
L. Lorente (2015)
Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study
S. A. Peeters (2015)
Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
F. Duits (2015)
Matrix metalloproteinases as therapeutic targets for stroke
Y. Yang (2015)
Targeting secondary injury in intracerebral haemorrhage—perihaematomal oedema
Sebastian Urday (2015)
Matrix metalloproteinase 9–mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy
Lingzhi Zhao (2015)
Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict Hemorrhagic Transformation of Lesion in Ischemic Stroke Patients Treated with Thrombolysis: Results from the MAGIC Study
B. Piccardi (2015)
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
J. Orbe (2015)
Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.
J. Broderick (2017)
Elevated MMP-1 and TIMP-1 are related with acute cerebral infarction patients with diabetes mellitus
Jin-xia Zhang (2017)
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
S. A. Peeters (2017)
CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage
J. Rodríguez (2017)
Approach to Imaging in Patients with Spontaneous Intracranial Hemorrhage.
P. Kranz (2018)
Assessment and comparison of the max-ICH score and ICH score by external validation
F. Schmidt (2018)
Serum Markers of Blood-Brain Barrier Remodeling and Fibrosis as Predictors of Etiology and Clinicoradiologic Outcome in Intracerebral Hemorrhage
Matthew D. Howe (2018)
High Serum Level of Matrix Metalloproteinase-7 Is Associated With Increased Risk of Spontaneous Subarachnoid Hemorrhage
Martin Söderholm (2018)
Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage.
M. Selim (2018)
Association of functional MMP-2 gene variant with intracranial aneurysms: case-control genetic association study and meta-analysis
V. Alg (2018)
Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data
R. Al‐Shahi Salman (2018)
Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification.
A. Purroy (2018)
Assessment and comparison of the max-ICH score and ICH score by external validation. Neurology
F. A. Schmidt (2018)
a systematic review and meta-analysis of individual patient data
Al-Shahi Salman (2018)
case-control genetic association study and meta-analysis
Stroke genetics: discovery, biology, and clinical applications
M. Dichgans (2019)
Acute Management of Hypertension Following Intracerebral Hemorrhage
J. Haller (2019)
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
D. Hanley (2019)
Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients.
L. Lorente (2019)
High serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with spontaneous intracerebral hemorrhage.
L. Lorente (2019)
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III)
W. Ziai (2019)
Location-specific differences in hematoma volume predict outcomes in patients with spontaneous intracerebral hemorrhage
N. Ironside (2019)
Matrix Metalloproteases-Mediated Cleavage on β-Dystroglycan May Play a Key Role in the Blood–Brain Barrier After Intracerebral Hemorrhage in Rats
X. Zhang (2019)
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label
D F Hanley (2019)
a randomised, controlled, open-label, blinded endpoint phase 3 trial
discovery, biology, and clinical applications
M. Dichgans (2019)
Results from the MAGIC study
This paper is referenced by
Serum glucose and potassium ratio as a predictive factor for prognosis of acute intracerebral hemorrhage
Xiao-Yu Wu (2021)